centerforbiosimilars12 小时
Long-Term Data Support Use of Eculizumab Biosimilar as Soliris Alternative in PNH
Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...
centerforbiosimilars1 天
Switching From Ustekinumab to Biosimilar SB17 Maintains Efficacy, Safety in Patients With ...
Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...
centerforbiosimilars2 天
Jeff Baldetti, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2 天
Mayuri Mathuria, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2 天
Eye on Pharma: Teva, Formycon, Celltrion Biosimilar Updates in Global Markets
Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...
centerforbiosimilars3 天
Skylar Jeremias
Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory announcements regarding new biosimilar products in Europe and Canada.
centerforbiosimilars3 天
Prateek Yadav, MPTh, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars3 天
Dan Danielson, RPh, MS
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars3 天
Chase Ibia, PharmD Candidate
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars3 天
No Disease Activity Changes After Children With IBD Switched to Infliximab Biosimilar
A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...